Jiangsu Simcere Pharmaceutical Co.
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Jiangsu Simcere Pharmaceutical Co. sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Jiangsu Simcere Pharmaceutical Co.: 2 sponsored US clinical trials, 1 recruiting.
Jiangsu Simcere Pharmaceutical Co. sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Relapsed or Refractory Multiple Myeloma, with 1 trials.
Mid-pack sponsor footprint
Jiangsu Simcere Pharmaceutical Co. is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
2 total, page 1 of 1
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
NCT06375044
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors
NCT05781360
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Therapeutic Areas
What is open in the Jiangsu Simcere Pharmaceutical Co. pipeline
1 recruiting of 2 indexed (50% open).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Relapsed or Refractory Multiple Myeloma (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Jiangsu Simcere Pharmaceutical Co.: open-pipeline peers nationwide
Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Jiangsu Simcere Pharmaceutical Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
- Abcentra · 50% recruiting · 2 trials
Related
What to do with this Jiangsu Simcere Pharmaceutical Co. page
2 registered trials is a research-attention snapshot, not an endorsement of Jiangsu Simcere Pharmaceutical Co. or any single study.
- 1 of Jiangsu Simcere Pharmaceutical Co.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Relapsed or Refractory Multiple Myeloma is the condition Jiangsu Simcere Pharmaceutical Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Relapsed or Refractory Multiple Myeloma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Jiangsu Simcere Pharmaceutical Co. pipeline card: 2 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.